Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (111-120 of 205) with videos related to

Pageof 21
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
European Urology|June 8, 2011
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of responseDavid J Gallagher, Hikmat Al-Ahmadie, Irina Ostrovnaya, et al.
Scientific Reports|March 4, 2017
Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept StudyQingbo Yin, Sheng-Che Hung, Li Wang, et al.
Urologic Oncology|October 22, 2016
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancerMatthew I Milowsky, Matthew D Galsky, Michael J Morris, et al.
Urologic Oncology|December 11, 2012
12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary reportSam S Chang, Colin P N Dinney, S Machele Donat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Plos One|December 31, 2021
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Plos One|June 21, 2021
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
Clinical Genitourinary Cancer|April 11, 2020
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year ExperienceGopa Iyer, Christopher M Tully, Emily C Zabor, et al.
Pageof 21

Showing results (111-120 of 205) with videos related to

Sort By:
Pageof 21
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
European Urology|June 8, 2011
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of responseDavid J Gallagher, Hikmat Al-Ahmadie, Irina Ostrovnaya, et al.
Scientific Reports|March 4, 2017
Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept StudyQingbo Yin, Sheng-Che Hung, Li Wang, et al.
Urologic Oncology|October 22, 2016
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancerMatthew I Milowsky, Matthew D Galsky, Michael J Morris, et al.
Urologic Oncology|December 11, 2012
12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary reportSam S Chang, Colin P N Dinney, S Machele Donat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Plos One|December 31, 2021
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Plos One|June 21, 2021
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
Clinical Genitourinary Cancer|April 11, 2020
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year ExperienceGopa Iyer, Christopher M Tully, Emily C Zabor, et al.
Pageof 21